23rd Mar 2016 07:00
Motif Bio plc
("Motif" or the "Company")
Motif Bio to present at BIO-Europe Spring
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has been selected to present at the 10th International Partnering Conference, BIO-Europe Spring® taking place at the Kistamässan Convention Center in Stockholm, Sweden over April 4-6.
The presentation will be given by Dr. Graham Lumsden, CEO of Motif Bio and will take place in Room E6/7 (level 0) on Tuesday, April 5 2016 at 14:15 CET.
BIO-Europe Spring® is the springtime counterpart to EBD Group's flagship conference, BIO-Europe® and continues the tradition of providing life science companies with high calibre partnering opportunities. The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings.
For further information please contact:
Motif Bio plc Graham Lumsden (Chief Executive Officer) David Huang (Chief Medical Officer)
|
|
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Dan Bate Dominic Wilson
| +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) | +44 (0)203 861 6625 |
|
|
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0) 20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
|
|
MC Services AG (EUROPEAN IR) Raimund Gabriel
|
+49 (0)89 210 2280
|
About Motif Bio (www.motifbio.com)
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
Related Shares:
MTFB.L